Male Reproductive Cancers Resource Center
As our aging workforce expands, a decreasing number of young investigators are applying for National Institute of Health (NIH) R01-equivalent grants.
New biomarkers might revolutionize prostate cancer treatment, according to an educational presentation at the 2016 ASCO Annual Meeting in Chicago.
Male Reproductive Cancers News
Men with P. acnes found in their prostate tissue biopsy are more than 4 times as likely to develop prostate cancer as others.
More Male Reproductive Cancers Resources
This fact sheet answers some common questions about prostate cancer, bone scan, and metastasis.
This fact sheet reviews current prostate cancer screening tests, guidelines, PSA, and risk factors.
This fact sheet provides information on symptoms, pain, causes, and treatments for testicular, testicle cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Statistical Significance, Uncertainty, and KEYNOTE-010
- Chlorhexidine Dressing Reduces May Reduce Incidence of Catheter-related Bloodstream Infections
- Gene-expression Prognostic Signatures Guide Adjuvant Chemotherapy of Early-stage Breast Cancer
- PD-1 and Checkpoint Inhibitors May Benefit Some Patients With SCLC
- Carfilzomib Efficacious Against Multiple Myeloma Regardless of Cytogenetic Abnormalities
- Breast Cancer (Invasive) Treatment Regimens
- Breast Cancer (Recurrent or Metastatic) Treatment Regimens
- TRUS-biopsy Poorly Detects Prostate Cancer
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Mental Disorder Risk High Among Patients With Cancer During Treatment and Before Diagnosis
- The Future of the Biomedical Research Workforce in the United States
- Dosage Adjustment to Increase Plasma Trough Levels Requires Investigation for Treatment of RCC and Sarcoma
- VSIG10L Gene May Signify Susceptibility to Esophageal Adenocarcinoma
- Researchers Identify the "Cell of Origin" in Basal Cell Carcinoma
- Half of Patients in Remission 11 Months After Nilotinib Discontinuation